<DOC>
	<DOCNO>NCT02946216</DOCNO>
	<brief_summary>The study aim explore prevalence ALK/ROS1/MET mutation assess ctDNA sample EGFR-wildtype NSCLC</brief_summary>
	<brief_title>ALK/ROS1/MET Mutations Plasma ctDNA Patients With NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Histologically confirm stage IIIB/IV NSCLC ; Histologically confirm adenocarcinoma ; EGFRwildtype NSCLC ; Provision blood ( plasma ) sample ctDNA test ; Patient must able comply protocol ; Provision blood ( plasma ) sample ctDNA test ; As judged investigator , evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic renal disease ) ; Histologically confirm small cell lung cancer metastatic tumor ; Patient histologic cytological diagnosis ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>